Skip to content

Cystatin c and Beta 2 Microglobulin in Thalassemic Children.

Cystatin C and Beta 2 Microglobulin as Biochemical Markers for Early Detection of Renal Impairment in Children With Beta Thalassemia

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03881917
Enrollment
150
Registered
2019-03-20
Start date
2019-11-01
Completion date
2021-03-01
Last updated
2019-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Disease

Keywords

renal impairment

Brief summary

Beta thalassemia has many complications on many systems as the renal system.So early detection of renal impairment is required in those children to decrease complications of this nephropathy.

Detailed description

Thalassemia syndromes are the most common single gene disorders worldwide especially in developing countries. The use of regular and frequent blood transfusions in patients with beta thalassemia major has improved patients' life spans and quality of life, but can lead to chronic iron overload. Many factors contribute to the functional abnormalities found in beta thalassemia patients such as decreased red cell life span, rapid iron turnover, tissue deposition of excess iron and also, specific iron chelators can affect kidneys. The success in management of patients of beta thalassemia has led to chronic hemosiderosis in different organs like liver and heart and long-term complications in other organs like pancreas and kidneys have recently been studied. The evidence of proximal tubular damage has been observed in beta thalassemia patients. Also, low-molecular-weight proteinuria has been found in almost all patients. Unlike other organs, it is unclear whether kidney damage results solely from intravascular haemolysis, chronic transfusion or as a complication of iron chelation therapy. Although the early identification of patients at high risk of renal impairment is of great importance as it may allow specific measures to be taken to delay renal impairment, there are limited studies about renal dysfunction in pediatric thalassemic patients. Thus, in this study we will use different measurements for early detection of renal impairment even if the patients have no symptoms to handle with the disease in its reversible stage before being irreversible. Beside the usual investigations of renal function we will measure cystatin c and beta2 microglobulin as early markers of renal impairment.

Interventions

DIAGNOSTIC_TESTCystatin c and beta 2 microglobulin kits

Kits for measurement concentration

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Years to 18 Years
Healthy volunteers
Yes

Inclusion criteria

* Children with beta thalassemia from the age of 1 year to 18 years.

Exclusion criteria

* Children who have other hematological or chronic disease.

Design outcomes

Primary

MeasureTime frameDescription
mean difference of cystatin c and beta 2 microglobulin concentrations with normal rangebaselineAnalysis of the results to differentiate the affected from non affected patients

Contacts

Primary ContactMohamed Naguib Khairy, M.B.B.Ch
mohamed_ibrahim@med.au.edu.eg+201091921973

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026